ASP2957 clinical trials
ASP2957 is listed as a product in 2 authorised or ongoing trials in the EU clinical trials register (CTIS). All registered phases are Phase 1. The sponsor is Astellas Gene Therapies Inc. It does not appear under this name in the ClinicalTrials.gov records behind our other registers.
Patient leaflets for ASP2957
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
ASP2957 in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product named ASP2957. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Long-term Follow-up Study in Male Participants with X-linked Myotubular Myopathy Treated with ASP2957
2025-524467-21-00 · CTIS ↗ · Musculoskeletal Diseases
|
Phase 1 | Authorised | Astellas Gene Therapies Inc | France |
|
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants with Invasive Ventilator-dependent X-linked Myotubular Myopathy
2025-523213-29-00 · CTIS ↗ · Musculoskeletal Diseases
|
Phase 1 | Authorised | Astellas Gene Therapies Inc | France |
Conditions studied with ASP2957
1 conditionSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Astellas Gene Therapies Inc | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Questions about ASP2957 trials
How many clinical trials are testing ASP2957?
2 authorised or ongoing trials in the EU clinical trials register (CTIS) list a product named ASP2957, as of the registry sync on 8 November 2026. It is not named in the ClinicalTrials.gov records behind our Ireland, UK, USA, India and China registers.
Who sponsors ASP2957 clinical trials?
The lead sponsor is Astellas Gene Therapies Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public EU CTIS records by a daily sync. Nothing here describes how ASP2957 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ASP2957 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, product names, phase, status, sponsor, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ASP2957 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.